CN Mobile Logo

Search form


ASCO 2011

ASCO 2011

Blase Polite, MD, assistant professor of medicine at the University of Chicago and the track leader for the GI Colorectal Scientific Program Committee at ASCO, discusses the latest research in the field of colorectal cancer.

David Ryan, MD, discusses his debate with Paul H. Sugarbaker, MD, from the ASCO session “Intraperitoneal Chemotherapy and Cytoreductive Surgery in Colon Cancer” and how in his view this type of treatment, as presented to the patient, creates a certain dynamic between the surgeon and medical oncologist, one of hope vs reality.

Don Dizon, MD, Brown University, discusses the paradigm shift in the treatment of endometrial cancer with the use of medical therapy, including chemotherapy with biologics, mTOR inhibitors combined with chemotherapy, and targeted therapies.

Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.

Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs— ipilimumab (Yervoy) and vemurafenib (Zelboraf)—for the treatment of metastatic melanoma.

Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials.

Nancy Dawson, MD, discusses PSA dynamics: the significance of PSA levels and PSA doubling time—the marker which currently provides the most information—and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.


Subscribe to ASCO 2011 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.